The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

The Banking of Biosimilars: Insights From a Leading Health Economist

February 4th 2025

By Skylar Jeremias

Article

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.

BioRationality: No More Biosimilars—Just Biogenerics

February 3rd 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.

Understanding Biosimilars Through Education and PBM Formulary Perspective

February 2nd 2025

By Cameron Santoro

Video

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.

Biosimilars Rheumatology Roundup: January 2025

February 1st 2025

By Skylar Jeremias

Article

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

Welcome Wezlana: The First Stelara Biosimilar to Launch in the US

January 31st 2025

By Skylar Jeremias

Article

January 1 marks the launch of the first biosimilar referencing Stelara (ustekinumab) in the US, ushering in a new class of lower-cost medicines for patients with rheumatic and gastrointestinal conditions.

FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar

January 31st 2025

By Skylar Jeremias

Article

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.

The Top 5 Biosimilar Articles for the Week of January 27

January 31st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 27, 2025.

Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis

January 30th 2025

By Skylar Jeremias

Article

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar

January 30th 2025

By Cameron Santoro

Article

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese regulatory agency approved a Stelara biosimilar.

Integrating Biosimilars Into Retina and Neurology Practices Requires Careful Planning

January 29th 2025

By Derek Burns, PharmD, MBA, BCPS, BCSCP

Article

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.